Product
GFB-887
2 clinical trials
14 indications
Indication
Kidney DiseasesIndication
Diabetic NephropathiesIndication
Kidney DiseaseIndication
Focal SegmentalIndication
NephrosisIndication
LipoidIndication
Urologic DiseasesIndication
Diabetes ComplicationsIndication
Diabetes MellitusIndication
Endocrine System DiseasesIndication
GlomerulonephritisIndication
NephritisIndication
Focal Segmental GlomerulosclerosisIndication
lipid urologic diseaseClinical trial
A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change DiseaseStatus: Terminated, Estimated PCD: 2022-11-01
Clinical trial
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney DiseasesStatus: Terminated, Estimated PCD: 2022-11-02